Response to the Letter to the Editor: "Lazertinib in EGFR-Mutated NSCLC with CNS Metastases: Reinforcing the Role of Third-Generation TKIs through Pooled Analysis".
APA
Cho BC, Kim Y (2026). Response to the Letter to the Editor: "Lazertinib in EGFR-Mutated NSCLC with CNS Metastases: Reinforcing the Role of Third-Generation TKIs through Pooled Analysis".. Clinical lung cancer, 27(1), 72-73. https://doi.org/10.1016/j.cllc.2025.11.013
MLA
Cho BC, et al.. "Response to the Letter to the Editor: "Lazertinib in EGFR-Mutated NSCLC with CNS Metastases: Reinforcing the Role of Third-Generation TKIs through Pooled Analysis".." Clinical lung cancer, vol. 27, no. 1, 2026, pp. 72-73.
PMID
41364949
같은 제1저자의 인용 많은 논문 (5)
- Free latissimus dorsi muscle transfer using an endoscopic technique.
- MAGELLAN arms B1 and B3: Durvalumab plus chemotherapy with and without oleclumab in treatment-naïve metastatic non-small-cell lung cancer.
- Durvalumab Plus Chemotherapy in Patients With -Mutated Advanced NSCLC Whose Disease Progressed on First-Line Osimertinib: ORCHARD.
- Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial.
- Correction of Severe Secondary Cleft Lip Nasal Deformity.